Education
About Us
Working with TipRanks
Follow Us
Progyny (PGNY)
NASDAQ:PGNY
PGNY Stock Chart & Stats
$26.71
$0.60(3.43%)
At close: 4:00 PM EST
$26.71
$0.60(3.43%)
Day’s Range― - ―
52-Week Range$13.86 - $27.51
Previous CloseN/A
Volume466.97K
Average Volume (3M)1.65M
Market Cap
$2.17B
Enterprise Value$1.62B
Total Cash (Recent Filing)$345.21M
Total Debt (Recent Filing)$24.73M
Price to Earnings (P/E)41.2
Beta0.56
Next Earnings
Mar 02, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding86,211,655
10 Day Avg. Volume1,172,489
30 Day Avg. Volume1,646,466
Financial Highlights & Ratios
PEG Ratio-3.15
Price to Book (P/B)3.74
Price to Sales (P/S)1.35
P/FCF Ratio9.08
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue1.28
Enterprise Value/Gross Profit5.58
Enterprise Value/Ebitda17.02
Forecast
1Y Price Target
$28.57Price Target Upside6.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.65
Revenue Forecast (FY)$1.28B
Bulls Say, Bears Say
Bulls Say
Client RetentionClient renewals remained at nearly 100% providing confidence in the stability of the business following the high profile loss of Amazon.
Financial PerformanceProgyny posted a fourth consecutive quarter of revenue and adj-EBITDA upside to estimates and raised FY'25 guidance across metrics.
Share RepurchaseThe announced $200 million share repurchase authorization should provide support for the stock.
Bears Say
Client AcquisitionProgyny closed over 80 new clients representing roughly 900,000 lives, which is short of the 1 million lives targeted.
Drug Pricing ImpactPurchasing the drugs cash-pay via TrumpRx likely would not count toward out-of-pocket maximums, and without coordination could result in unsuccessful cycles.
Market SpeculationInvestors are likely speculating on the impact of an affordable direct-to-consumer option for IVF drugs on Progyny Rx demand.
Progyny News
PGNY FAQ
What was Progyny’s price range in the past 12 months?
Progyny lowest stock price was $13.86 and its highest was $27.51 in the past 12 months.
What is Progyny’s market cap?
Progyny’s market cap is $2.17B.
When is Progyny’s upcoming earnings report date?
Progyny’s upcoming earnings report date is Mar 02, 2026 which is in 78 days.
How were Progyny’s earnings last quarter?
Progyny released its earnings results on Nov 06, 2025. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.127 by $0.023.
Is Progyny overvalued?
According to Wall Street analysts Progyny’s price is currently Undervalued.
Does Progyny pay dividends?
Progyny does not currently pay dividends.
What is Progyny’s EPS estimate?
Progyny’s EPS estimate is 0.15.
How many shares outstanding does Progyny have?
Progyny has 86,211,655 shares outstanding.
What happened to Progyny’s price movement after its last earnings report?
Progyny reported an EPS of $0.15 in its last earnings report, beating expectations of $0.127. Following the earnings report the stock price went up 24.209%.
Which hedge fund is a major shareholder of Progyny?
Currently, no hedge funds are holding shares in PGNY
Progyny Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.57 (6.96% Upside)
$28.57 (6.96% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 389.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.78%
12-Months-Change
Fundamentals
Return on Equity
11.37%
Trailing 12-Months
Asset Growth
20.49%
Trailing 12-Months
Company Description
Progyny
Progyny, Inc. is a leading fertility benefits management company based in the United States, specializing in providing comprehensive fertility solutions to employers and their employees. The company operates within the healthcare sector, offering a range of services that include fertility treatment coverage, access to a network of fertility specialists, and personalized care management. Progyny's core products are designed to enhance reproductive health and support individuals and couples on their paths to parenthood, thereby addressing a critical need in family-building benefits.
PGNY Company Deck
PGNY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Progyny had a strong performance this quarter with revenue and profitability exceeding expectations, a successful selling season, and a high client renewal rate. However, challenges included slightly lower than expected new covered lives and impact from a large client loss. Overall, the positive aspects significantly outweigh the negative, indicating strong business momentum.View all PGNY earnings summariesPGNY Stock 12 Month Forecast
Average Price Target
$28.57
▲(6.96% Upside)
Technical Analysis
Ownership Overview
2.25% Insiders
33.90% Mutual Funds
17.50% Other Institutional Investors
20.15% Public Companies and
Individual Investors